BiotechTube

Enzalutamide + Abiraterone acetate

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostatic Neoplasms, Castration-Resistant

Conditions

Prostatic Neoplasms, Castration-Resistant

Trial Timeline

Jul 24, 2023 → Feb 14, 2025

NCT ID
NCT05968599

About Enzalutamide + Abiraterone acetate

Enzalutamide + Abiraterone acetate is a pre-clinical stage product being developed by Astellas Pharma for Prostatic Neoplasms, Castration-Resistant. The current trial status is completed. This product is registered under clinical trial identifier NCT05968599. Target conditions include Prostatic Neoplasms, Castration-Resistant.

What happened to similar drugs?

15 of 20 similar drugs in Prostatic Neoplasms, Castration-Resistant were approved

Approved (15) Terminated (0) Active (5)
✅Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
✅Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
✅Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
✅Tamsulosin OCASAstellas PharmaApproved
✅Tamsulosin OCAS + PlaceboAstellas PharmaApproved
✅TadalafilEli LillyApproved
✅ErtapenemMerckApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05968599Pre-clinicalCompleted

Competing Products

20 competing products in Prostatic Neoplasms, Castration-Resistant

See all competitors
ProductCompanyStageHype Score
Tadalafil + PlaceboEli LillyPhase 3
40
Placebo + tadalafilEli LillyPhase 3
40
Abemaciclib + Darolutamide + LHRH agonist/antagonistEli LillyPhase 1
29
Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
43
tadalafil + placeboEli LillyPhase 2
35
Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue MedicationDaiichi SankyoPhase 1/2
39
Placebo tamsulosin hydrochloride OCAS 0.4 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg + tamsulosin hydrochloride OCAS 0.4 mg + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
40
Novel hormonal therapyAstellas PharmaPre-clinical
26
ASP3550Astellas PharmaPhase 2
35
Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
43
Novel hormonal therapyAstellas PharmaPre-clinical
26
tamsulosin 0.4mgAstellas PharmaPre-clinical
22
Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
43
Enzalutamide + NSAA + LHRHA or Surgical CastrationAstellas PharmaPhase 3
44
enzalutamide + bicalutamideAstellas PharmaPhase 2
35
Tamsulosin OCASAstellas PharmaApproved
43
degarelixAstellas PharmaPhase 2
35
Tamsulosin OCAS + PlaceboAstellas PharmaApproved
43
Tadalafil + PlaceboEli LillyPhase 2
35
TadalafilEli LillyApproved
43